Clinical Trials Browser

Interventional × Lung Neoplasms × Docetaxel × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT06012435 2026-05-27

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06780098 2026-05-26

MK-3475-01I

Phase 2 Recruiting

Lung Neoplasms

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04310007 2026-05-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06635824 2026-05-05

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Phase 3 Active not recruiting

Lung Neoplasms

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05132075 2026-04-21

KontRASt-02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01630733 2026-04-15

ENSPIRIT

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06881784 2026-03-12

RASolve 301

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT06484491 2026-01-30

HyDose

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Phase 2 Active not recruiting

Lung Neoplasms

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT06228326 2025-10-24

KYANITE-1

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00532155 2025-09-10

VITAL

Phase 3 Completed

913 enrolled 16 charts

Carcinoma, Lung Neoplasms

NCT00284778 2025-07-24

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04364620 2025-04-06

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

Phase 2 Completed

35 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02922764 2025-03-26

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Phase 1 Completed

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT01828112 2025-02-07

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Phase 3 Completed

231 enrolled 33 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2 Recruiting

Lung Neoplasms

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2 Completed

166 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06421298 2024-05-20

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Phase 2 Recruiting

Lung Neoplasms

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00118131 2023-08-15

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

49 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00471432 2023-08-04

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Phase 1 Completed

BreastGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male

NCT00301808 2023-05-06

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01763671 2023-03-14

Ultimate

Phase 3 Completed

Lung Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT00970684 2022-08-16

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

13 enrolled 9 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03041181 2022-07-11

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Phase 2 Terminated

3 enrolled 11 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT00103389 2022-06-27

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01207011 2022-04-12

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Phase 3 Completed

Lung Neoplasms

NCT01059188 2022-03-11

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00193427 2022-03-03

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

75 enrolled 7 charts

Lung Neoplasms

NCT02531737 2021-08-10

REFRACT

Phase 2 Completed

Lung Neoplasms

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Withdrawn

Lung Neoplasms

NCT03402048 2020-11-04

EPIC

Phase 3 Unknown

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00054184 2020-10-05

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00835471 2020-09-29

NVALT10

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00271505 2020-05-11

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Phase 2 Completed

43 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00227708 2020-02-13

Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms